How I Treat Relapsed/Refractory Multiple Myeloma: Navigating Treatment Selection, Sequencing, and Personalized Care in an Evolving Therapeutic Landscape

In this OncLive® Insights program, Dr. Joshua Richter and Dr. Marco Davila provide an evidence-based discussion on the evolving management of relapsed/refractory multiple myeloma (RRMM), with a focus on optimizing treatment selection, sequencing, and personalized patient care. The conversation explores how recent clinical evidence is influencing earlier integration of advanced therapies, while emphasizing patient identification, disease risk assessment, and individualized treatment planning. Dr. Richter and Dr. Davila discuss practical considerations that extend beyond efficacy data, including appropriate timing of referral to specialized centers, multidisciplinary collaboration, bridging therapy, and coordination between community and academic practices. Through case-based discussions, they examine real-world approaches to managing patients with standard-risk and high-risk disease, highlighting factors that influence therapeutic decision-making across different clinical scenarios. The program also addresses patient quality of life, caregiver engagement, and remaining challenges in improving access to innovative therapies, providing clinicians with practical, balanced insights for delivering personalized care to patients with relapsed/refractory multiple myeloma.